CSIMarket Company Name, Ticker, Competitors, else..
 
Cartesian Therapeutics Inc   (NASDAQ: RNAC)
 
Price: $9.2800 $-0.32 -3.333%
Day's High: $9.539999961853027 Week Perf: -10.6 %
Day's Low: $ 9.14 30 Day Perf: 18.97 %
Volume (M): 90,784 52 Wk High: $ 11.00
Volume (M$): $ 0 52 Wk Avg: $7.99
Open: $9.54 52 Wk Low: $5.60



 Market Capitalization (Millions $) 249
 Shares Outstanding (Millions) 27
 Employees 75
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -152
 Cash Flow (TTM) (Millions $) -62
 Capital Exp. (TTM) (Millions $) 4

Business Description




   Company Address: 7495 New Horizon Way Frederick 21703 MD
   Company Phone Number: 348-8698   Stock Exchange / Ticker: NASDAQ RNAC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -0.7%    
ONC   -3.33%    
REGN   -3.55%    
TEVA   -2.38%    
UTHR   -0.49%    
VTRS   -0.18%    
• View Complete Report
   



Clinical Study

Breakthrough in Autoimmune Therapy Cartesian Therapeutics Shines with Descartes-08 in SLE and Myasthenia Gravis Trials

Published Fri, Nov 14 2025 9:54 AM UTC

A New Dawn for Autoimmune Diseases: Cartesian Therapeutics Descartes-08 Shows Promising Results in SLE and Myasthenia GravisIn a landscape where autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis pose significant challenges to patients and clinicians alike, Cartesian Therapeutics is making impressive strides with its mRNA cell therapy, Des...
Shares

A New Chapter in Biotech: Cartesian Therapeutics Hires Top Talent with Inducement Grants,

Published Fri, May 2 2025 11:05 AM UTC

Cartesian Therapeutics Solidifies Talent Strategy with Inducement Grants Amid Steady Revenue GrowthFREDERICK, Md. May 2, 2025 Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a prominent player in the biotechnology sector noted for its pioneering cell therapy efforts targeting autoimmune diseases, has announced a strategic move to attract skilled talent. On May 1, 2025, the...
Management Announcement

Cartesian Therapeutics Boosts Talent Acquisition with New Inducement Grant Amidst Steady Revenue Performance

Published Thu, Mar 6 2025 12:05 PM UTC

In a strategic move to attract top-tier talent, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a pioneering biotechnology company focused on mRNA cell therapies for autoimmune diseases, has recently announced the granting of an employment inducement award to a new employee. This initiative underscores the organization s commitment to enhancing human capital, a critical compone...
Shares

Cartesian Therapeutics Strengthens Workforce with Strategic Stock Options Amid Market Resilience,

Published Thu, Feb 6 2025 12:05 PM UTC

Cartesian Therapeutics Reinforces Talent Acquisition with Inducement Grants Amid Market DynamicsFREDERICK, Md. February 6, 2025 Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a prominent player in the clinical-stage biotechnology sector and innovator in mRNA cell therapies for autoimmune diseases, has taken a significant step towards fortifying its workforce. On February 3, ...
Shares

Empowering Innovation: Cartesian Therapeutics Expands Team with Strategic Stock Options Amid Market Challenges,

Published Tue, Jan 7 2025 12:05 PM UTC

Frederick, Md. January 07, 2025 In a continuing demonstration of confidence in its strategic direction, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a trailblazer in the development of mRNA cell therapies for autoimmune diseases, has announced the issuance of new employment inducement grants to three promising additions to its team. This move marks another significant s...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 140.40
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.44
Working Capital Ratio 7.65
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.9 $
Revenues (TTM) 0.07 $
Cash Flow (TTM) -
Cash 4.42 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 23,667
Net Income per Employee (TTM) -2,023,653
Receivable Turnover Ratio (TTM) 2.9
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -33973.08 %
Net Margin (MRQ) -50233.33 %
Net Cash Flow Margin (MRQ) -8330.77 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Cartesian Therapeutics Inc's Segments
Segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.